Significant correlation seen between lifestyle and both cognitive function and A\u03b242\/40 ratio<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 13, 2024 (HealthDay News) — For patients with mild cognitive impairment (MCI) or early dementia due to Alzheimer disease (AD), comprehensive lifestyle changes may improve cognition and function, according to a study published online June 7 in Alzheimer’s Research & Therapy<\/em>.<\/p>\n Dean Ornish, M.D., from Preventive Medicine Research Institute in Sausalito, California, and colleagues conducted a randomized controlled phase 2 trial involving 51 individuals aged 45 to 90 years with MCI or early dementia due to AD and a Montreal Cognitive Assessment score of 18 or higher. Changes in cognition and function tests were examined after 20 weeks of an intensive multidomain lifestyle intervention versus a wait-list usual-care control group.<\/p>\n The researchers found significant between-group differences in the Clinical Global Impression of Change (CGIC), Clinical Dementia Rating-Sum of Boxes (CDR-SB), and Clinical Dementia Rating Global (CDR Global), as well as borderline significant differences in the Alzheimer’s Disease Assessment Scale (ADAS-Cog) after 20 weeks. Compared with the control group, which worsened in all four measures, the intervention group showed improvement in cognition and function on the CGIC, CDR-Global, and ADAS-Cog and showed significantly less progression on the CDR-SB. There was an increase in the \u00ce\u00b2-amyloid (A\u00ce\u00b2)42\/40 ratio in the intervention group and a decrease in the control group. A significant correlation was seen between lifestyle and both cognitive function and the plasma A\u00ce\u00b242\/40 ratio. Improvement in the microbiome was only seen in the intervention group.<\/p>\n “These findings support longer follow-up and larger clinical trials to determine the longer-term outcomes of this intensive lifestyle medicine intervention in larger groups of more diverse AD populations,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n